e-learning
resources
Stockholm 2007
Monday 17.09.2007
Pulmonary infections in the immunocompetent and immunocompromised host
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of nebulised colistimethate sodium on non-CF bronchiectasis with
pseudomonas aeruginosa
(preliminary report)
K. Dimakou, K. Tsikritsaki, K. Sagris, I. Dimitroulis, E. Akoumianaki, M. Toumbis (Athens, Greece)
Source:
Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host
Session:
Pulmonary infections in the immunocompetent and immunocompromised host
Session type:
Thematic Poster Session
Number:
2573
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Dimakou, K. Tsikritsaki, K. Sagris, I. Dimitroulis, E. Akoumianaki, M. Toumbis (Athens, Greece). The effect of nebulised colistimethate sodium on non-CF bronchiectasis with
pseudomonas aeruginosa
(preliminary report). Eur Respir J 2007; 30: Suppl. 51, 2573
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The effect of tobramycin nebulised solution in COPD patients with Pseudomonas aeruginosa in sputum (preliminary report)
Source: Eur Respir J 2004; 24: Suppl. 48, 409s
Year: 2004
Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Source: Eur Respir J 2002; 20: 658-664
Year: 2002
Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA).
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study
Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy
Year: 2020
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Daily versus weekly azithromycin in cystic fibrosis patients
Source: Eur Respir J 2007; 30: 487-495
Year: 2007
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Distribution of nebulised gentamicin in patients with bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004
Efficacy and safety of TOBI Podhaler in
Pseudomonas aeruginosa-
infected bronchiectasis patients: iBEST study
Source: Eur Respir J, 57 (1) 2001451; 10.1183/13993003.01451-2020
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept